DNAe to present its NGS Diagnostics Pipeline at 24th Annual Newsmakers in the Biotech Industry

London, UK and Carlsbad, CA, USA – 5 September 2017 – DNAe, the inventor of semiconductor DNA sequencing technology and developer of a new, game-changing test for bloodstream infections, announces that its Chief Business Officer, Nick McCooke will present an update on its first product, the LiDia™ bloodstream infections (BSI) test, at BioCentury’s 24th Annual Newsmakers in the Biotech Industry on 8th September in New York. DNAe will also outline its pipeline of diagnostic tests, including applications in sepsis, antibiotic resistant infections, flu and cancer.

Presentation
Time: 10:30 am - 10:55 am
Location: room 402/403, Millennium Broadway Hotel & Conference Center

Breakout session
Time: 11:00 am - 11:30 am
Location: room 401, Millennium Broadway Hotel & Conference Center

Nick McCooke will be available to meet whilst at the event. To arrange a time, email contact@DNAe.com or use the conference partnering system.

—Ends—

About DNAe – www.dnae.com
DNAe is commercializing its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing LiDia™, its sample-to-result genomic analysis platform, combining DNA Electronics Inc.’s Pathogen Capture System with its own portfolio of semiconductor-based genomic technologies, trademarked Genalysis®. The LiDia™ range of tests will enable DNA analysis directly on a microchip, providing rapid and accurate results from a user-friendly system.

DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. LiDia™ launches with the LiDia™ Bloodstream Infection (BSI) test, a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

A private company, with bases in London, UK and Carlsbad, CA, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting-edge life sciences companies.
About NewsMakers in the Biotech Industry

*NewsMakers* presents a hand-picked group of public biotech companies whose corporate and regulatory milestones will drive stock prices. *NewsMakers* is recognized as the industry's key venue for companies to take their story to Wall Street each fall. Thus, *NewsMakers* remains the best opportunity for business development executives and key members of the institutional investment and analyst communities to compare notes and assess the industry landscape.

Last year, more than 500 delegates congregated at *NewsMakers*, including money managers who controlled more than $600 billion in equity assets, with over $50 billion dedicated to healthcare and $15 billion dedicated to biotech.

Contact Details

**DNAe**
Dr Steve Allen, Chief Executive Officer (London, UK)  
Tel: +44 (0)20 7036 2100
Sam Reed, President, U.S. Office (Washington, USA)  
Tel: +1 202 779 2640

**Instinctif Partners (media relations)**
Sue Charles / Ashley Tapp / Alex Bannister / Deb Bell  
Email: DNAe@instinctif.com

Tel: +44 (0)20 7457 2020